Form 4: Phathom CEO Steven Basta Boosts Direct Stock Holdings

Phathom Pharmaceuticals CEO Steven Basta increased his direct ownership by 30,536 shares after performance stock unit vesting and tax-related share surrender.

Summary

• Steven L. Basta, President and CEO of Phathom Pharmaceuticals, Inc., reported transactions on December 17, 2025.
• He acquired 62,038 shares of Common Stock at a price of $0, which represents shares issued upon the vesting of performance stock units (PSUs) granted on April 3, 2025.
• The vesting was based on the achievement of performance criteria determined to be satisfied on December 17, 2025.
• Concurrently, Mr. Basta disposed of 31,502 shares of Common Stock at a price of $15.36 per share.
• These disposed shares were surrendered to the Issuer to satisfy tax withholding obligations related to the PSU vesting.
• Following these transactions, Mr. Basta's direct beneficial ownership of Common Stock stands at 113,786 shares.

Sentiment

Score: 7

Explanation: The CEO's net increase in direct ownership, even after accounting for tax-related share sales, generally signals confidence in the company's future prospects and the achievement of performance goals.

Positives

• Steven L. Basta, President and CEO, increased his direct beneficial ownership of Phathom Pharmaceuticals Common Stock by a net of 30,536 shares.
• The acquisition of 62,038 shares resulted from the vesting of performance stock units, indicating the achievement of pre-defined performance criteria.

Negatives

• 31,502 shares were surrendered to the Issuer to cover tax withholding obligations, representing a disposition of shares.

Future Outlook

This Form 4 filing reports past transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a standard insider transaction report (Form 4) detailing changes in beneficial ownership for a key executive. It does not provide broader industry context or trends, but rather reflects company-specific executive compensation and stock ownership.

Stakeholder Impact

• Shareholders may view the CEO's increased direct ownership as a positive signal of management's confidence in the company's value and future performance.
• The vesting of performance stock units indicates that certain pre-defined corporate performance criteria have been met, which could be positive for investors.

Key Dates

Recommendation

The CEO's net increase in direct beneficial ownership, resulting from the vesting of performance stock units, suggests strong insider confidence in Phathom Pharmaceuticals. This action, even with the standard tax-related share disposition, is generally interpreted as a bullish signal for the company's future performance and valuation, warranting a 'buy' recommendation.

Keywords

Phathom Pharmaceuticals, PHAT, Steven L. Basta, Insider Transaction, Form 4, CEO, Performance Stock Units, PSU Vesting, Executive Compensation, Stock Ownership